Jazz Pharmaceuticals（JAZZ）株式概要
ジャズ・ファーマシューティカルズ plcは、米国、欧州、および国際的に医薬品の特定、開発、商業化を行う。 詳細
JAZZ Community Fair Values
Create NarrativeSee what 54 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Jazz Pharmaceuticals plc 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$252.16 |
| 52週高値 | US$265.05 |
| 52週安値 | US$118.04 |
| ベータ | 0.36 |
| 1ヶ月の変化 | 3.57% |
| 3ヶ月変化 | 5.33% |
| 1年変化 | 111.77% |
| 3年間の変化 | 81.18% |
| 5年間の変化 | 86.43% |
| IPOからの変化 | 1,322.22% |
最新ニュース
ナラティブ更新 • Aug 15
JAZZ: HER2 GEA Approval And Rare Epilepsy Deal Will Reshape Oncology Leadership
Analysts have lifted their fair value estimate for Jazz Pharmaceuticals from $257.00 to $281.35, citing higher modeled revenue growth, stronger profit margins, and a richer future P/E assumption that reflect recent price target increases across the Street and confidence in the company's expanding oncology and rare-epilepsy portfolio. Analyst Commentary Street research on Jazz Pharmaceuticals has been active, with a cluster of higher price targets and fresh coverage reflecting updated views on execution, growth mix, and risk around key franchises and pipeline assets.Seeking Alpha • Aug 12
Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout
Summary Jazz Pharmaceuticals acquires Actio Biosciences for $820 million upfront, targeting rare KCNT1+ epilepsy with ABS-1230, a registrational-stage precision therapy. JAZZ delivered record Q2 2026 revenues of ~$1.2 billion, with strong year-on-year growth in key assets like Xywav (+13%) and Zepzelca (+42%). Despite a competitive narcolepsy landscape and $4.4 billion in debt, JAZZ's diversified portfolio, robust cash position, and M&A track record support a Buy rating. ABS-1230, with multiple FDA designations, could add $200–$400 million in peak sales if approved, I estimate, further strengthening JAZZ's epilepsy franchise. Read the full article on Seeking AlphaRecent updates
ナラティブ更新 • Aug 15
JAZZ: HER2 GEA Approval And Rare Epilepsy Deal Will Reshape Oncology Leadership
Analysts have lifted their fair value estimate for Jazz Pharmaceuticals from $257.00 to $281.35, citing higher modeled revenue growth, stronger profit margins, and a richer future P/E assumption that reflect recent price target increases across the Street and confidence in the company's expanding oncology and rare-epilepsy portfolio. Analyst Commentary Street research on Jazz Pharmaceuticals has been active, with a cluster of higher price targets and fresh coverage reflecting updated views on execution, growth mix, and risk around key franchises and pipeline assets.Seeking Alpha • Aug 12
Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout
Summary Jazz Pharmaceuticals acquires Actio Biosciences for $820 million upfront, targeting rare KCNT1+ epilepsy with ABS-1230, a registrational-stage precision therapy. JAZZ delivered record Q2 2026 revenues of ~$1.2 billion, with strong year-on-year growth in key assets like Xywav (+13%) and Zepzelca (+42%). Despite a competitive narcolepsy landscape and $4.4 billion in debt, JAZZ's diversified portfolio, robust cash position, and M&A track record support a Buy rating. ABS-1230, with multiple FDA designations, could add $200–$400 million in peak sales if approved, I estimate, further strengthening JAZZ's epilepsy franchise. Read the full article on Seeking Alpha
ナラティブ更新 • Aug 01
JAZZ: Ziihera Launch Expectations Will Drive Future Multiple Compression Risk
The analyst price target for Jazz Pharmaceuticals has moved higher, with the fair value estimate shifting from $205.58 to $212.63. This change is supported by analysts citing a greater focus on higher-value oncology products, updated views on Ziihera and other oncology launches, and ongoing management of sleep-franchise risks.ナラティブ更新 • Jul 18
JAZZ: Oncology Launch Execution Will Drive Future Multiple Compression Risk
Analysts have lifted the fair value estimate for Jazz Pharmaceuticals slightly, from about $200.51 to $205.58. This change reflects updated assumptions around a shifting product mix toward oncology and a series of higher Street price targets tied to upcoming launches and sleep-franchise risk management.ナラティブ更新 • Jun 23
JAZZ: HER2 GEA Priority Review Will Support Future Oncology Leadership Narrative
Analysts have lifted the central analyst price target for Jazz Pharmaceuticals stock from $225.53 to $257.00, pointing to stronger conviction in Ziihera's potential uptake in gastroesophageal adenocarcinoma and biliary tract cancer, a firmer outlook for the oncology portfolio, and perceived resilience of the Xywav franchise. Analyst Commentary Recent research on Jazz Pharmaceuticals highlights a clear split between bullish analysts focused on Ziihera driven growth and oncology expansion, and more cautious voices focused on neurology concentration risk and competitive pressure.分析記事 • Jun 18
Jazz Pharmaceuticals (JAZZ) Stock Could Be 73% Below Fair Value After Recent Pullback
Jazz Pharmaceuticals stock reaction puts recent performance in focus With no single headline event driving Jazz Pharmaceuticals (JAZZ) today, the stock’s recent performance and fundamentals take center stage, inviting investors to reassess how its current pricing lines up with reported results. See our latest analysis for Jazz Pharmaceuticals. At a share price of $226.93, Jazz Pharmaceuticals has recently given back some of its shorter term gains, with a 7 day share price return that declined...
ナラティブ更新 • Jun 06
JAZZ: Oncology Readouts And CNS Durability Will Support Future Upside Potential
Analysts have lifted their fair value estimate for Jazz Pharmaceuticals to $304.19 from $263.59, citing higher modeled revenue growth, stronger profit margins supported by views on Ziihera and zanidatamab, and confidence in Xywav patent protections that they argue could justify a modestly lower future P/E multiple. Analyst Commentary Recent Street research on Jazz Pharmaceuticals presents a mixed but generally constructive tone, with several bullish analysts pointing to patent clarity on Xywav and the commercial opportunity for Ziihera and zanidatamab as key support pillars for their models.ナラティブ更新 • May 23
JAZZ: Oncology Execution Risks Will Drive Future Multiple Compression Concerns
Analysts have lifted the fair value estimate for Jazz Pharmaceuticals from $188.00 to about $200.51, citing a higher assumed future P/E multiple. They link this to growing confidence in the broader Ziihera and zanidatamab opportunities, even as they factor in slightly lower long term profit margins and ongoing competitive pressure on legacy neurology drugs.分析記事 • May 13
We Think You Can Look Beyond Jazz Pharmaceuticals' (NASDAQ:JAZZ) Lackluster Earnings
The market was pleased with the recent earnings report from Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ), despite the...分析記事 • May 08
Jazz Pharmaceuticals plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ) investors will be delighted, with the company turning in some strong numbers...ナラティブ更新 • Apr 28
JAZZ: HER2 GEA Data Will Support Future Oncology Leadership Thesis
Analysts have nudged the price target on Jazz Pharmaceuticals higher to about $226, reflecting updated views on margins, central nervous system revenue durability, and upcoming oncology contributions following recent Q4 results and refreshed models. Analyst Commentary Recent Street research on Jazz Pharmaceuticals has centered on refreshed models following Q4 results, updated revenue guidance, and the expected contribution from oncology assets alongside the core central nervous system portfolio.ナラティブ更新 • Apr 13
JAZZ: CNS Cash Flows And Upcoming Oncology Launches Will Shape Execution Risks
Analysts have increased their average price target on Jazz Pharmaceuticals by $13 to $255, citing more supportive assumptions around revenue growth, profit margins and a slightly lower future P/E following the recent Q4 results and updated guidance. Analyst Commentary Recent research on Jazz Pharmaceuticals has largely centered on updated price targets and ratings following the company’s Q4 report and new guidance.ナラティブ更新 • Mar 30
JAZZ: CNS Cash Flows And HER2 Franchise Will Shape Oncology Execution Risks
Narrative Update on Jazz Pharmaceuticals Analysts have lifted price targets on Jazz Pharmaceuticals by roughly $10 to $45 into a $224 to $275 range, citing steady central nervous system demand, updated Ziihera and zanidatamab expectations following HERIZON-GEA data, and recent Q4 results that aligned with or modestly exceeded prior forecasts. Analyst Commentary Recent research on Jazz Pharmaceuticals has been broadly constructive, with several firms adjusting price targets higher after Q4 results and the HERIZON GEA data updates.ナラティブ更新 • Mar 16
JAZZ: HER2 Data And CNS Cash Flows Will Balance Oncology Execution Risks
The analyst price target for Jazz Pharmaceuticals has been adjusted slightly higher to reflect a $1 increase in fair value to $188, lower modeled revenue growth at 2.92%, a higher profit margin assumption at 21.90%, and a reduced future P/E of 13.95, as analysts point to a resilient central nervous system franchise, updated views on Ziihera and zanidatamab opportunities, and recent Q4 results and guidance. Analyst Commentary Recent research coverage points to generally constructive sentiment on Jazz Pharmaceuticals, with a cluster of higher price targets anchored to the company’s central nervous system portfolio and oncology pipeline, including Ziihera and zanidatamab.ナラティブ更新 • Mar 02
JAZZ: Oncology Readouts And CNS Durability Will Drive Future Upside Potential
Our analyst fair value estimate for Jazz Pharmaceuticals has moved from $230.00 to about $263.59, as analysts factor in stronger margin expectations, a slightly higher discount rate, and ongoing Street enthusiasm around Ziihera and the broader oncology pipeline following recent Q4 updates and HERIZON-GEA data presentations. Analyst Commentary Recent Street research has leaned constructive on Jazz Pharmaceuticals, with multiple bullish analysts revisiting their models following Q4 results and the latest HERIZON-GEA data.ナラティブ更新 • Feb 16
JAZZ: HER2 Practice-Changing GEA Data Will Drive Future Oncology Leadership
Narrative Update Overview The analyst price target for Jazz Pharmaceuticals has moved higher, with our fair value estimate rising from $213 to $219.40 as analysts factor in stronger Ziihera and zanidatamab potential, supported by recent HERIZON-GEA data and updated Street research. Analyst Commentary Recent Street research on Jazz Pharmaceuticals has been largely constructive, with multiple firms updating their work after the detailed HERIZON-GEA-01 readout and related discussions around Ziihera and zanidatamab.ナラティブ更新 • Feb 02
JAZZ: Practice-Changing HER2 Data Will Drive Oncology Upside And Rebalance Legacy Risks
Analysts have raised their price targets on Jazz Pharmaceuticals by approximately $10 to $30 per share, citing what they describe as practice-changing HERIZON GEA data for Ziihera and a clearer oncology pipeline driver as key supports for the higher valuations. Analyst Commentary Across recent research notes, analysts have been revising their views on Jazz Pharmaceuticals primarily around the HERIZON GEA data for Ziihera and what it could mean for the oncology portfolio.ナラティブ更新 • Jan 19
JAZZ: Practice-Changing HER2 Data Will Rebalance Oncology Potential And Legacy Risks
Jazz Pharmaceuticals' updated analyst price target has edged down by US$1 to US$187 as analysts factor in slightly higher growth and margin assumptions, supported by recent HERIZON-GEA-01 data that they describe as practice changing for Ziihera and potentially supportive of new standard-of-care use across several HER2+ cancer settings. Analyst Commentary Across recent research, most firms are reacting to the HERIZON-GEA-01 data by lifting their Jazz Pharmaceuticals price targets and highlighting Ziihera and zanidatamab as key value drivers.ナラティブ更新 • Jan 05
JAZZ: Oncology Data Will Reshape Revenue Mix While Legacy Headwinds Persist
We are raising our Jazz Pharmaceuticals fair value estimate to $188 from $147 as analysts boost price targets following positive HERIZON-GEA-01 data for Ziihera, which they see as a potential new standard of care and a multibillion dollar revenue driver. Analyst Commentary Street research following the HERIZON-GEA-01 topline readout has turned broadly constructive on Jazz Pharmaceuticals, with multiple firms lifting price targets and reiterating positive ratings.ナラティブ更新 • Dec 18
JAZZ: HER2-Positive GEA Breakthrough Will Drive Future Oncology Leadership
Analysts have nudged their fair value estimate for Jazz Pharmaceuticals higher to $213.00 from $208.50, reflecting stronger long term revenue growth expectations and a richer future P/E multiple, supported by increasingly bullish views on Ziihera's potential to become a new standard of care in HER2 positive GEA and a key oncology growth driver. Analyst Commentary Bullish analysts are largely focused on the upside from Ziihera's HERIZON-GEA-01 data, with multiple research shops lifting price targets and embedding higher long term oncology growth into their models.ナラティブ更新 • Dec 04
JAZZ: HER2-Positive GEA Success Will Drive Future Oncology Leadership And Upside
Our fair value estimate for Jazz Pharmaceuticals has nudged higher to $208.50 from $206.38, reflecting analysts' upward revisions to price targets as they factor in expectations of stronger long term revenue growth and profitability. This is driven by Ziihera's potential as a new standard of care in HER2 positive GEA and broader oncology indications.ナラティブ更新 • Nov 20
JAZZ: Recent Positive Trial Data Will Drive Future Leadership In HER2-Positive Oncology
Analysts have increased their price target for Jazz Pharmaceuticals from approximately $186 to $206 per share. They cite improved revenue growth projections and recent strong clinical data supporting the potential of Ziihera as a standard-of-care therapy in HER2-positive cancers.分析記事 • Nov 18
Improved Revenues Required Before Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock's 25% Jump Looks Justified
Despite an already strong run, Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ) shares have been powering on, with a gain of...ナラティブ更新 • Aug 30
Emerging Therapies And Portfolio Expansion Will Shape Future Markets
Analysts have modestly raised their price targets for Jazz Pharmaceuticals, driven by growing confidence in Modeyso's commercial prospects and expanded market potential, partially offset by persistent challenges in other segments, resulting in a new consensus target of $186.47. Analyst Commentary Bullish analysts are increasingly positive on the commercial potential of Modeyso following its recent approval, citing higher-than-expected pricing, a dedicated launch strategy, and strong patient/prescriber interest.株主還元
| JAZZ | US Pharmaceuticals | US 市場 | |
|---|---|---|---|
| 7D | 1.3% | 2.3% | -0.3% |
| 1Y | 111.8% | 53.6% | 19.9% |
業界別リターン: JAZZ過去 1 年間で53.6 % の収益を上げたUS Pharmaceuticals業界を上回りました。
リターン対市場: JAZZ過去 1 年間で19.9 % の収益を上げたUS市場を上回りました。
価格変動
| JAZZ volatility | |
|---|---|
| JAZZ Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 9.0% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: JAZZ 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: JAZZの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2003 | 2,890 | Renee Gala | www.jazzpharma.com |
ジャズ・ファーマシューティカルズ社（Jazz Pharmaceuticals plc）は、米国、欧州、および世界各国において、医薬品の特定、開発、および販売を行っています。同社は、カタプレクシー、ナルコレプシーに伴う日中の過度の眠気（EDS）、および特発性過眠症（IH）の治療薬として「Xywav」を提供しています。 レノックス・ガストー症候群（LGS）、ドラベ症候群（DS）、または結節性硬化症（TSC）に伴う発作の治療薬「エピディオレックス（Epidiolex）」； 急性リンパ性白血病またはリンパ芽球性リンパ腫の治療薬「Rylaze」；急性リンパ性白血病およびリンパ芽球性リンパ腫の治療薬「Enrylaze」；プラチナ製剤ベースの化学療法中または治療後に病勢が進行した転移性小細胞肺がんの治療薬「Zepzelca」； HER2陽性胆道がんの治療薬「Ziihera」；H3 K27M変異を有するびまん性正中線グリオーマの治療薬「Modeyso」；および重度の静脈閉塞性疾患の治療薬「Defitelio」。 また、HER2陽性の胃食道腺癌（GEA）および胆道がん（BTC）の治療を目的とした第3相臨床試験段階の「ザニダタマブ」； H3 K27M変異を有するびまん性グリオーマの治療薬「ドルダビプロン」；および新規診断された治療関連急性骨髄性白血病の治療薬「ヴィクセオス」。さらに、同社は、乳がんの術前補助療法および術後補助療法を目的とした「ザニダタマブ」； 高リスクMDS、新規診断で未治療の高リスクAML患者、およびゲノム解析により層別化されたデ・ノボの中等度リスクまたは不良リスクAMLの治療を目的とした「Vyxeos」；ならびに、第2相臨床試験段階にある褐色細胞腫および傍神経節腫の治療を目的とした「JZP3507」を開発している。 さらに、RafおよびRas変異を有する腫瘍の治療薬として「JZP815」、固形がんに対するIFN「INDUKIN」分子を用いた「JZP898」、および欠神てんかんの治療薬として「JZP047」を開発しており、これらは第1相臨床試験段階にある。 同社は、Redx Pharma plc、Autifony Therapeutics Limited、Zymeworks Inc.、住友製薬株式会社、Werewolf Therapeutics, Inc.、および AbCellera Biologics Inc. と提携契約を締結している。Jazz Pharmaceuticals plc は 2003 年に設立され、アイルランドのダブリンに本社を置いている。
Jazz Pharmaceuticals plc 基礎のまとめ
| JAZZ 基礎統計学 | |
|---|---|
| 時価総額 | US$16.43b |
| 収益（TTM） | US$940.75m |
| 売上高(TTM) | US$4.60b |
17.4x
PER（株価収益率3.6x
P/SレシオJAZZ は割高か？
公正価値と評価分析を参照収益と収入
| JAZZ 損益計算書（TTM） | |
|---|---|
| 収益 | US$4.60b |
| 売上原価 | US$397.85m |
| 売上総利益 | US$4.20b |
| その他の費用 | US$3.26b |
| 収益 | US$940.75m |
直近の収益報告
Jun 30, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 14.49 |
| グロス・マージン | 91.35% |
| 純利益率 | 20.45% |
| 有利子負債／自己資本比率 | 90.6% |
JAZZ の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/19 03:26 |
| 終値 | 2026/08/19 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Jazz Pharmaceuticals plc 19 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。48
| アナリスト | 機関 |
|---|---|
| Brian Skorney | Baird |
| Joel Beatty | Baird |
| null null | Baird |